TABLE 1.

Risk proportions of muscular system adverse events after coadministration of sacubitril/valsartan and statins.

Drug A	Drug B	Adverse reaction	A and B	A, no B	B, no A	No A, no B
sacubitril/valsartan	atorvastatin	muscle spasms	8/788	326/68,726	1715/82,809	78,652/8,883,870
		myalgia	6/788	264/68,726	2,514/82,809	68,379/8,883,870
		muscular weakness	7/788	281/68,726	1,217/82,809	44,118/8,883,870
		musculoskeletal pain	3/788	119/68,726	554/82,809	24,744/8,883,870
		rhabdomyolysis	5/788	62/68,726	550/82,809	13,921/8,883,870
		myopathy	23/788	726/68,726	2,657/82,809	165,192/8,883,870
		myositis	1/788	5/68,726	89/82,809	3,016/8,883,870
		blood creatine phosphokinase increased	5/788	123/68,726	436/82,809	10,154/8,883,870
		musculoskeletal discomfort	7/788	214/68,726	764/82,809	44,608/8,883,870
	rosuvastatin	muscle spasms	7/1,022	326/68,726	1,669/77,853	78,652/8,883,870
		myalgia	10/1,022	264/68,726	2,725/77,853	68,379/8,883,870
		muscular weakness	12/1,022	281/68,726	1,070/77,853	44,118/8,883,870
		musculoskeletal pain	1/1,022	119/68,726	588/77,853	24,744/8,883,870
		rhabdomyolysis	6/1,022	62/68,726	1,130/77,853	13,921/8,883,870
		myopathy	10/1,022	726/68,726	3,097/77,853	165,192/8,883,870
		myositis	1/1,022	5/68,726	104/77,853	3,016/8,883,870
		blood creatine phosphokinase increased	1/1,022	123/68,726	42/77,853	10,154/8,883,870
		musculoskeletal discomfort	3/1,022	214/68,726	1,310/77,853	44,608/8,883,870
	simvastatin	muscle spasms	6/854	326/68,726	1731/102,851	78,652/8,883,870
		myalgia	5/854	264/68,726	2,755/102,851	68,379/8,883,870
		muscular weakness	6/854	281/68,726	1,290/102,851	44,118/8,883,870
		musculoskeletal pain	13/854	119/68,726	590/102,851	24,744/8,883,870
		rhabdomyolysis	5/854	62/68,726	1,296/102,851	13,921/8,883,870
		myopathy	23/854	726/68,726	2,678/102,851	165,192/8,883,870
		myositis	1/854	5/68,726	120/102,851	3,016/8,883,870
		blood creatine phosphokinase increased	2/854	123/68,726	40/102,851	10,154/8,883,870
		musculoskeletal discomfort	4/854	214/68,726	1,114/102,851	44,608/8,883,870